Why the Next Industrial Revolution Could Start 250 Miles Above Earth
A deep dive into the future of orbital factories, space manufacturing, AI automation, and the trillion-dollar space economy.
About the Author
Imran Valiani | Sales Director, PCB Electronics Manufacturing — 20+ years working with major Bay Area and global tech clients. Founder of Silicon to Software, where I write about the hardware layer — PCB fab, AI gear, autonomous systems, and cyber — the stuff most tech writers have never touched. Literally. Follow: X @SiToSoftware | LinkedIn
Table of Contents
Okay, start here: a drug. Cooked in Space. Landed in the Utah desert. And it was better than the one made in a $50 million cleanroom on Earth.
I know how that sounds. I thought the same thing. But that’s not a press release — that’s a peer-reviewed result from a ChemRxiv study, and it’s the clearest sign I’ve seen that something real is happening 250 miles up. (Technically 370–460 km, since the ISS drifts as atmospheric drag pulls it down between reboosts — but “250 miles” is close enough for the conversation we’re about to have.)
The International Space Station is already making drugs, printing human tissue, and growing specialty semiconductor structures for researchers on the ground. Today. Not in ten years. Today. I’ve been watching this Space for a while, and I think most people — including many in industry — are sleeping on what it actually means.
So let’s get into it.
Forget What You Think You Know About Space
Most people hear “space manufacturing” and picture astronauts with wrenches. That’s not this.
I think the better mental model is: what if gravity were a bug in your process? Because for certain products — pharmaceutical crystals, fiber optic preforms, biological tissue — it genuinely is. Gravity causes three things that wreck manufacturing quality:
- Sedimentation — heavy bits sink during liquid processing and seed impurities throughout your whole batch
- Convective currents — heat differences push fluid around and trash the crystal lattice you were trying to grow
- Buoyancy effects — light materials float up during solidification and create weak spots throughout the end product
Kill gravity, and all three largely go away. Per a May 2025 in-space manufacturing analysis by Robotics & Automation News, microgravity produces materials with fewer defects and greater structural uniformity — including ultra-pure fiber optics with signal-loss profiles you can’t achieve on the ground.
Now — and I want to get this right, because most coverage gets it wrong — vacuum is not the same as clean. I’ve noticed that a lot of “space = no contamination” skips past the actual engineering. In vacuum, materials off-gas: they release trapped gases and volatile organic compounds (VOCs) that drift and condense as thin films on every surface they find, including your sensitive hardware. NASA has whole qualification standards for this — every material going to orbit gets a thermal-vacuum bake-out under NASA outgassing standards before it flies. The contamination problem doesn’t go away. It changes shape.
Heat is brutal too. No air means no convection, which means heat from any manufacturing process can only leave by conduction or radiation. You need purpose-built radiators. You need to budget your power density carefully. And every 90-minute orbit includes roughly 45 minutes of sunlight and 45 minutes of darkness — thermal swings, over and over, stressing everything. Loose particles float. Forever. Which is why cutting and grinding — subtractive manufacturing — is essentially off the table in orbit without specialized containment.
Then there’s radiation, and I think this is the one that gets undersold the most. Low Earth Orbit exposes every piece of hardware to galactic cosmic rays, solar particle events, and trapped protons from the Van Allen belts. These cause single-event upsets (SEUs) — bit-flips in memory and logic that can crash a system mid-process. Plus cumulative total ionizing dose (TID) that degrades electronics slowly over the mission. The ISS crosses the South Atlantic Anomaly — a zone of elevated trapped-particle flux — on every orbit.
According to peer-reviewed work in MDPI Electronics (2023), SEUscan’tt be meaningfully blocked by adding shielding—the particles carry enough energy to punch through any practical mass of material. You design around it instead: error-correcting code (ECC) memory, radiation-hardened compute, fault-tolerant architectures, redundancy baked in everywhere.
On the other hand — and maybe I’m wrong about the framing here — all of these constraints are known and either solved or solvable. Per the March 2025 review in MDPI Manufacturing, they’re well-documented challenges, not unknowns. The reason orbital manufacturing is compellingisn’tt that it avoids hard problems. It’s that for specific high-value product types, the upside of removing gravity structurally outweighs the cost of managing everything else. That’s the whole argument. There is space for everything. Space for certain things.
So What Does It Actually Look Like Right Now?
Start with the drug because this is the one that made me stop and re-read it twice.
Varda Space Industries — a startupI’dd been vaguely tracking — launched a compact, uncrewed capsule to low Earth orbit (LEO) aboard a SpaceX Falcon 9 in June 2023. The capsule was a pharmaceutical manufacturing unit. The target: ritonavir, an antiretroviral HIV drug.
Seven months later, the thing came screaming back through the atmosphere at hypersonic speeds, over 18,000 miles per hour, and landed in Utah on February 21, 2024.
Here’s what came back. Per the joint ChemRxiv study from Varda and Improved Pharma LLC, the mission converted ritonavir Form II — the stable form — into the metastable Form III, which has better bioavailability and is notoriously hard to produce consistently on Earth. Microgravity kills the convective currents and sedimentation that disrupt crystal lattice formation. You get cleaner, more uniform growth throughout the batch.
The crystals survived reentry. Form held.
I know whatyou’ree thinking — one drug, one mission, not a factory. Fair. But according toVarda’ss own platform documentation, microgravity processing has the potential to improve shelf life, bioavailability, and formulation consistency for small-molecule drugs and biologics — outcomes that are active in early-stage research, not yet validated in clinical trials. And compelling enough to raise $329 million in funding, including a $187M Series C in July 2025 led by Natural Capital and Shrug Capital. Think about every drug that requires cold-chain shipping because it falls apart at room temperature. Consider monoclonal antibodies thatwon’tt crystallize uniformly in a ground-based facility. Space might be the only place some of these processes work at all.
Who Else Is Building Up There?
Redwire Space
Varda gets the headlines, but Redwire is arguably doing more actual work on the ISS right now than any other commercial outfit. Per their own June 2024 press release (NYSE: RDW), they had ten active payload facilities on the station at that time — more than any other commercial entity. By December 2025, that grew to eleven, per the full-year 2025 earnings report. The count shifts as experiments cycle through resupply missions, butit’ss been going in one direction.
I think the history here matters and gets glossed over. The Additive Manufacturing Facility (AMF)—RRedwire’sflagship platform, the first permanent commercial manufacturing system in LEO—wasn’t built by Redwire. It was built by Made In Space, which launched it in 2016. Redwire acquired Made In Space in 2020. Per the ISS National Lab database, the AMF has produced over 200 tools and components on-orbit, printing in ABS, PEI-PC, and HDPE. Good platform. Solid track record.
But honestly? The bioprinting work is the part that keeps pulling me back.
Redwire runs a separate platform — the 3D BioFabrication Facility (BFF), originally built by Techshot Inc. before Redwire acquired it — and in July 2023, it used it to bioprint the first human knee meniscus in orbit as part of the BFF-Meniscus-2 investigation. —live human cells. Cultured for two weeks in the Advanced Space Experiment Processor (ADSEP) and returned to Earth in September 2023 on Crew-6.
Then in April 2024, the same BFF platform bioprinted live human heart tissue in orbit. Without scaffolding. PerRedwire’s official May 8, 2024, press release via Business Wire (NYSE: RDW): no scaffolding needed, because in microgravity the soft tissue holds its own three-dimensional shape — ititdoesn’ttollapse under gravity the way it does on Earth, where you need chemical thickeners or physical scaffolds to keep the structure intact during the print. (That last detail is the one I keep telling people about. It sounds fake. ItIt’sot.)
The implications for regenerative medicine aren’t coming—they’re being tested right now in pre-clinical research settings, which is where they need to be before anyone makes a clinical claim.
The NASA ODME Program. Here’s
He doesn’t get enough attention. NASA’s n-Demand Manufacturing of Electronics (ODME) program is building a high-precision inkjet printer capable of producing ReRAM (Resistive Random-Access Memory) chips in microgravity. The team includes Intel, Axiom Space, TEL (Tokyo Electron Limited), Arizona State University, and the University of Wisconsin — per Factories ininSpace’srbital microfabrication documentation.
I want to be clear about scope, because this gets hyped wrong constantly. This is not a challenge to TSMC. At all. Modern high-volume chip production relies on extreme ultraviolet (EUV) lithography, sub-3nm overlay precision, and process control at the atomic scale — gravity is not the limiting factor there. What orbital manufacturing targets are a completely different tier: exotic crystal substrates, radiation-hardened niche parts, low-volume specialty components that are genuinely hard to grow uniformly under gravity. The ODME approach uses electrohydrodynamic (EHD) printing — non-contact, direct-deposit, no photomasks — for exactly that low-volume, high-value use case. Parabolic flight testing was completed; ISS deployment was targeted for 2024–2025.
Sierra Space and Astral Materials
In December 2024, Sierra Space signed memoranda of understanding with Astral Materials and Space Forge to develop microgravity semiconductors on the upcoming Dream Chaser vehicle. Astral Materials put it plainly: “Our technology uses microgravity as a manufacturing tool that can only be accessed in space.” Hard to argue with that framing.
The Money Part
At the end of the day, none of this matters if the numbers don’t work. So let’s do the numbers.
Launch costs have dropped tenfold over the past two decades, per a SpaceNews analysis from April 2024 — driven mainly by SpaceX’s reuse model. Annual satellite deployment has been growing by roughly 50% year over year. But — and this is the part people forget — $/kg to orbit isn’t the whole cost. Insurance, payload qualification, integration, reentry certification, orbital debris mitigation: all real overhead, all modeled separately by serious aerospace investors. The full cost stack needs to compress, not just the launch price.
That said, when your product sells for hundreds of thousands of dollars per kilogram — pharmaceutical crystals, ZBLAN fluoride fiber-optic preforms, specialty semiconductor substrates — the math starts working in ways that don’t apply to a communications satellite.
The big-picture projections: Morgan Stanley Research projects the global space industry will grow to over $1.1 trillion by 2040. Goldman Sachs has independently put it at roughly $1 trillion by the same date. Bank of America Merrill Lynch equity research is projected to reach $2.7 trillion by 2045. Those figures span the whole space economy — launch, comms, remote sensing. In-space manufacturing is the part where you’re actually making physical stuff. That wedge is still wide open.
The Factory can’t have a human boss on-site. Here’s
Here’s something I’ve noticed that doesn’t come up often enough: you physically cannot staff these factories with people.
The ISS was designed for a crew of seven —that’s the binding constraint, though. The binding constraint is the ECLSS (Environmental Control and Life Support System) capacity, and the fraction of that crew time that’s actually free for commercial manufacturing work is tiny. Future commercial stations face the same wall. At scale, these facilities have to run on their own.
That means the full stack:
- Machine vision for in-process quality checks
- Autonomous robotic arms for handling and assembly
- Autonomous control systems running preprogrammed process sequences
- Remote monitoring with near-zero human intervention
Current platforms — RedRedwire’s F and BFF, VarVarda’s Capsule — run deterministic, preprogrammed autonomous sequences. That’s ML. Worth being precise. But Redwire is actively closing the gap: in May 2024, they became a founding corporate sponsor of the Center for Aerospace Autonomy Research (CAESAR) at Stanford, investing in machine learning, computer vision, and autonomous reasoning for space vehicles. Their MSTIC semiconductor platform — which completed a pathfinder mission on the ISS in 2024 — is already described by Redwire as “an autonomous semiconductor manufacturing platform,” C O Al Tadros in the CAESAR announcement: “AI-enhanced capabilities could be transformative for in-space servicing, GNC and RPO autonomy, and a range of complex mission requirements.”
I’ve found that the companies with the most credible progress in orbital manufacturing are also the ones most deeply involved in terrestrial automation work. Space forces the timeline.
A Bit of History (Bear With Me)
Every major industrial shift required two things: a new physical environment that changed what was possible, and a drop in the cost of getting there.
Coal made the first one go. Electricity is the second. Silicon and software are the third.
I think — and maybe I’mI’mtting too clean a bow on this — the fourth one is microgravity and vacuum as manufacturing conditions, made accessible by falling launch costs, run by systems that don’t need a person on-site. The output isn’t two. It’s finished goods: purer drugs, lower-loss fiber, novel crystal structures, tissue you can grow without a scaffold.
Earth’s gravity isn’t just physics. For certain processes, it’s a bug. We’ve been working around it for centuries because we had no choice.
What to Watch — Practically Speaking, Don’t
DonDon’teat the big picture for now. Here’s specific stuff worth tracking:
Reentry economics. VarVarda’sdel — capsule up, product made, capsule down — is the near-term playbook. The ratio that matters: payload value per kg versus full-station cost per kg. When that math works, this industry moves fast.
ZBLAN fiber. Made InSpace (now Redwire) has been developing ZBLAN fluoride fiber optic cable for years. Microgravity-made ZBLAN has dramatically lower signal attenuation than Earth-made versions. If it scales commercially, long-haul fiber infrastructure gets disrupted.
The drug pipeline. Varda is publicly moving from small molecules to biologics — specifically monoclonal antibody crystallization. Multi-billion-dollar segment. Real unsolved formulation problems. Worth watching closely.
Station handover. The ISS is scheduled for decommissioning around 2030. NASNASA’smmercial Low Earth Orbit Destinations (CLD) program is now funding successors. Whoever builds those stations owns the factory floor. That’s a figure of speech.
The Honest Part
I want to be real here: the gap between “we proved it works” and ” this is a scalable industry” is enormous. And I’d be doing you a disservice to skip past that.
Costs need to fall more. Return logistics need to become a boring routine. The products that benefit most from microgravity are — almost by design — the hardest ones to make, which means the debugging phase takes years, not quarters.
The regulatory piece is the one I think about most. Here’s the case study: VarVarda’s 1 capsule finished its ritonavir crystallization within weeks of the June 2023 launch. Done. But the capsule couldn’t come home — the FAA hadn’t issued a reentry license under the legacy Part 431 framework. It sat in orbit for six more months, burning power and operational life, waiting. TecTechCrunch’s November 2025 interview with Varda CEO Will Bruey, compressing latency remains a top priority.
On the other hand — I’m focused on the bottlenecks — the FAA just consolidated everything under Part 450 as of March 10, 2026: one performance-based framework replacing four legacy rule sets, designed to cut per-mission overhead. And the numbers speak: per FAAFAA’s announcement, FY2025 saw 199 licensed commercial launches and reentries. In 2015, that number was nine. That’s incremental progress. That’s structural change.
The physician isn’t anywhere. Gravity will still break crystal lattice formation tomorrow, exactly as it does today.
The only question is how fast everything else catches up.
Based on what landed in a Utah desert in February 2024 — I think the answer is: faster than the industry is ready for.
This post was written with AI assistance. See my full AI disclosure.
Sources
- NASA ISS Reference Page — nasa.gov
- Kennedy Space Center FAQ — kennedyspacecenter.com
- Robotics & Automation News — May 2025 in-space manufacturing analysis
- Redwire Corporation press releases — rdw.com
- ISS National Lab — AMF and BFF facility pages
- 3DPrint.com — Ken Savin interview, October 2024
- Varda Space Industries / Improved Pharma LLC — ChemRxiv preprint, 2024
- TechCrunch — Will Bruey interview, November 2025
- MDPI Manufacturing — in-space manufacturing review, March 2025
- MDPI Electronics — SEU analysis, 2023
- NASA TechPort — ODME Program, Project
#155248 - FactorieSpaceSpace — factoriesinspace.com
- Morgan Stanley Research — “Investment Implications of the Final Frontier.”
- G”ldman Sachs / U.S. Chamber of Commerce — space economy report
- Bank of America Merrill Lynch — equity research
- SpaceNew” —”Th” Trillion-Dollar Quest” in April 2024
- FAA — faa.gov/newsroom, March 2026
